Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
October 10 2016 - 9:00AM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company
that is developing the next generation of antivirals, announced
today that it will host a Key Opinion Leader (KOL) breakfast
focused on the growing burden of human rhinovirus (HRV) infections
in at-risk patient populations on Thursday, October 13, 2016 from
8:30 a.m. to 10:30 a.m. ET in New York.
The meeting will feature keynote presentations from Dr.
Frederick G. Hayden, Professor Emeritus of Infectious Diseases and
International Health at the University of Virginia, School of
Medicine, and Dr. Sebastian L. Johnston, Professor of Respiratory
Medicine and Allergy at Imperial College London and Director of the
Wellcome Trust Centre for Respiratory Infection. Additionally,
executives from Aviragen will provide an overview of the Company’s
antiviral pipeline and its ongoing Phase 2b SPIRITUS trial of
vapendavir for the treatment of HRV infections in patients with
moderate to severe asthma.
A live audio webcast of the event can be accessed under “Events
and Presentations” in the Investors section of the Company’s
website at www.aviragentherapeutics.com. An archived replay of the
webcast will be available for 30 days after the live event
concludes.
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of the
next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus (HRV)
respiratory infections in moderate-to-severe asthmatics currently
being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor in Phase 2 development for the treatment
and prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit
www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024